Arcutis Biotherapeutics, Inc.
ARQT
$26.23
$0.311.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 130.58% | 98.17% | 88.47% | 77.33% | 53.07% |
| Total Depreciation and Amortization | -56.11% | -50.87% | 138.23% | 117.48% | 346.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.50% | 2.28% | -0.79% | 6.33% | 3.68% |
| Change in Net Operating Assets | -104.74% | 43.81% | -130.96% | -160.04% | 2.97% |
| Cash from Operations | 160.02% | 124.33% | 94.98% | 80.58% | 62.99% |
| Capital Expenditure | 80.94% | 89.61% | -379.72% | -360.40% | -1,084.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -157.35% | -176.06% | -202.09% | 157.99% | 239.34% |
| Cash from Investing | -157.77% | -177.00% | -204.97% | 156.86% | 238.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 94.51% | 58.18% | -95.80% | -97.78% | -98.19% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 108.67% | 108.03% | -89.47% | -135.82% | -136.16% |
| Foreign Exchange rate Adjustments | -395.59% | 128.48% | 171.49% | -286.57% | 164.15% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -226.20% | 86.39% | -65.43% | -425.21% | 44.03% |